Can Boehringer's Stiolto beat the plague of payer arm-twisting on respiratory meds?

It's a tough field out there for makers of respiratory drugs, who've been cutting prices as they vie for prime formulary positioning with payers. Boehringer's Spiriva has already taken a sales hit as a result, but now, the German pharma is hoping new combo med Stiolto can turn things around. It'll be going up against some competition from GlaxoSmithKline's ($GSK) Anoro, though, which itself has struggled mightily on the access front. More from FiercePharmaMarketing